Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

It came as the FTSE 100 giant revealed a rise in sales as weakness in its vaccine division was offset by growth in speciality ...

This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

In an interview with Dr. Phil, the Kennedy offered false information about vaccine oversight and revealed a lack of understanding of new drug approvals.

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

In an interview with Dr. Phil, the health secretary offered false information about vaccine oversight and revealed a lack of ...

Dr. Marty Makary has been outspoken about vaccine mandates and other public health measures, so how does the Food and Drug ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

Kennedy has focused his healthcare crusade on his contention that American healthcare prioritizes treating chronic illnesses ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...